|Day's Range||33.97 - 34.21|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||28.65|
|Dividend & Yield||1.28 (3.75%)|
|1y Target Est||N/A|
Here are the names.
It hasn't been a great year so far for Opko Health, but the future could be brighter.
On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.